PAK6
PAK6 (p21 (RAC1) activated kinase 6, previously PAK5) is a serine/threonine protein kinase of the STE20 subfamily. It regulates gene transcription, notably by phosphorylating androgen receptor, and is linked to cytoskeleton regulation and cell survival. Browse Assay Genie's current range of PAK6 research reagents below, or read on for the biology behind the target.
PAK6 is a serine/threonine protein kinase that plays a role in the regulation of gene transcription. Its kinase activity is induced by various effectors, including androgen receptor (AR) and MAP2K6 (MAPKK6). PAK6 phosphorylates the DNA-binding domain of AR and thereby inhibits AR-mediated transcription. It also inhibits ESR1-mediated transcription. Beyond transcriptional control, PAK6 may contribute to cytoskeleton regulation through its interaction with IQGAP1, and it may protect cells from apoptosis through phosphorylation of BAD.
The PAK6 gene encodes a member of the p21-stimulated kinase family. Members of this family carry an amino-terminal Cdc42/Rac interactive binding (CRIB) domain and a carboxyl-terminal kinase domain, and they act in cytoskeleton rearrangement, apoptosis and the mitogen-activated protein (MAP) kinase signalling pathway. PAK6 belongs to the protein kinase superfamily, in the STE Ser/Thr protein kinase family and STE20 subfamily. UniProt records its subcellular location as the cytoplasm and nucleus, consistent with the report that it interacts with AR and translocates to the nucleus, where it is involved in transcriptional regulation. Alternative splicing results in multiple transcript variants.
HGNC lists the protein as p21 (RAC1) activated kinase 6, within the p21 (RAC1) activated kinase family, with earlier names p21(CDKN1A)-activated kinase 6 and p21 protein (Cdc42/Rac)-activated kinase 6. PAK5 is a previous symbol. Changes in PAK6 expression have been linked to prostate cancer, which makes sense given its relationship with AR. The mouse ortholog is Pak6.
PAK6 phosphorylates the AR DNA-binding domain and inhibits AR-mediated transcription, making it a focus for steroid receptor regulation studies.
Changes in PAK6 expression have been linked to prostate cancer, supporting its study alongside AR-dependent transcription.
PAK6 may regulate the cytoskeleton through IQGAP1 and belongs to a kinase family acting in cytoskeleton rearrangement and MAP kinase signalling.
PAK6 may protect cells from apoptosis through phosphorylation of BAD, so it is relevant to survival signalling research.
PAK6 is a serine/threonine kinase that regulates gene transcription. It phosphorylates the DNA-binding domain of androgen receptor, inhibiting AR-mediated transcription, and also inhibits ESR1-mediated transcription. It may also influence cytoskeleton regulation via IQGAP1 and protect cells from apoptosis by phosphorylating BAD.
Yes. PAK5 is a previous gene symbol. Earlier names include p21(CDKN1A)-activated kinase 6 and p21 protein (Cdc42/Rac)-activated kinase 6. UniProt names the protein serine/threonine-protein kinase PAK 6. Alternative splicing gives multiple transcript variants.
NCBI Gene reports that changes in PAK6 expression have been linked to prostate cancer. A mouse ortholog, Pak6, exists; check the datasheet of any product for its validated reactivity.
Other members of the p21 (RAC1) activated kinase family with pages at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q9NQU5; product specifications from Assay Genie datasheets.